FrancophonIA/ELRC3.0 huggingface dataset:
English: In particular, patients have experienced the following serious side effects:
Estonian: Pioglitasooni kasutavatel patsientidel on esinenud järgmisi kõrvaltoimeid:
English: Each tablet contains 75.54 mg of lactose monohydrate (see section 4.4).
Estonian: Üks 30 mg tablett sisaldab 75,54 mg laktoosmonohüdraati (vt lõik 4.4).
English: The usual starting dose is one tablet of 15 mg or 30 mg of pioglitazone to be taken once daily.
Estonian: Soovitatav annus on üks 15 mg või 30 mg pioglitasooni tablett üks kord ööpäevas.
English: Each tablet contains 37.77 mg of lactose monohydrate (see section 4.4).
Estonian: Üks 15 mg tablett sisaldab 37,77 mg laktoosmonohüdraati (vt lõik 4.4).
English: It is recommended, therefore, that patients treated with pioglitazone undergo periodic monitoring of liver enzymes.
Estonian: Seetõttu on soovitatav pioglitasoonravi saavatel patsientidel periooditi maksaensüüme jälgida.
English: How to store Glidipion
Estonian: Kuidas Glidipion`i säilitada
English: Read the package leaflet before use.
Estonian: Suukaudne Enne ravimi kasutamist lugege pakendi infolehte.
English: - if you have had diabetic ketoacidosis (a complication of diabetes causing rapid weight loss,
Estonian: - kui teil on olnud diabeetiline ketoatsidoos (diabeedi tüsistus, mis põhjustab kiiret kaalukaotust, iiveldust ja oksendamist) - kui teil on või on kunagi olnud kusepõievähk
English: You may take your tablets with or without food.
Estonian: Glidipion koos toidu ja joogiga Te võite tablette võtta söögiga või ilma söögita.
English: Special population
Estonian: Patsientide eripopulatsioonid
English: Blurred vision due to swelling (or fluid) at the back of the eye (frequency not known) has also been reported in patients taking pioglitazone.
Estonian: Pioglitasooni võtvatel patsientidel on samuti teatatud ka nägemise hägustumist turse (või vedeliku) tõttu silma tagaosas (esinemissagedus teadmata).
English: as triple oral therapy in combination with - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.
Estonian: kolme ravimi kombinatsioonis metformiini ja sufonüüluureaga, täiskasvanud (eriti ülekaalulistele) patsientidele, kelle glükeemiline insuliini kontroll on ebapiisav hoolimata suukaudsest kombinatsioonravist.
English: Metabolism and nutrition disorders hypo-glycaemia uncommon very common common appetite increased uncommon
Estonian: Ainevahetus- ja toitumishäired hüpoglükeemia aeg-ajalt väga sage söögiisu suurenemine aeg-ajalt
English: What you need to know before you take Glidipion Do not take Glidipion
Estonian: Mida on vaja teada enne Glidipion`i kasutamist
English: The other side effects that have been experienced by some patients when pioglitazone is taken with other antidiabetic medicines are:
Estonian: Patsientidel, kes on kasutanud pioglitasooni koos mõne teise diabeediravimiga, on esinenud järgmisi kõrvaltoimeid:
English: Common (may affect up to 1 in 10 people) - respiratory infection - abnormal vision - weight gain - numbness
Estonian: Sage (võib esineda kuni 1-l kasutajal 10'st) hingamisteede infektsioon nägemishäire kehakaalu tõus tuimus
English: Hypoglycaemia may occur in combination with sulphonylureas or insulin.
Estonian: Glidipion'i võib kasutada ka kombinatsioonis insuliiniga.
English: Uncommon (may affect up to 1 in 100 people) - sugar in urine, proteins in urine - increase in enzymes - spinning sensation (vertigo) - sweating - tiredness - increased appetite
Estonian: - suhkur uriinis, valgud uriinis - maksaensüümide aktiivsuse suurenemine - vertiigo (pearinglus) - higistamine - väsimus - söögiisu suurenemine
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED karp
English: Following initiation of therapy with pioglitazone, it is recommended that liver enzymes be monitored periodically based on clinical judgement.
Estonian: Määratud pioglitasoonravi korral oleks soovitatav maksaensüüme kontrollida perioodiliselt, olenevalt kliinilisest vajadusest.
English: Actavis Ltd. Tel: +35621693533
Estonian: Tel: +35621693533
English: However, certain medicines are especially likely to affect the amount of sugar in your blood: - gemfibrozil (used to lower cholesterol) - rifampicin (used to treat tuberculosis and other infections) Tell your doctor or pharmacist if you are taking any of these.
Estonian: rifampitsiin (kasutatakse tuberkuloosi ja teiste infektsioonide raviks) Informeerige oma arsti, kui te kasutate mõnda neist.
English: Infections and infestations upper respiratory tract infection common common common common common bronchitis common sinusitis uncommon uncommon uncommon uncommon uncommon
Estonian: Infektsioonid ja infestatsioonid Ülemiste hingamisteede infektsioon bronhiit sinusiit aeg-ajalt aeg-ajalt aeg-ajalt aeg-ajalt aeg-ajalt
English: common common uncommon macular oedema not known not known not known not known not known
Estonian: Ülitundlikkus ja allergilised reaktsioonid teadmata teadmata teadmata teadmata teadmata
English: Medicinal product subject to medical prescription.
Estonian: B. MÜÜGILOA TINGIMUSED Retseptiravim.
English: Co-administration of pioglitazone with rifampicin (an inducer of cytochrome P450 2C8) is reported to result in a 54% decrease in AUC of pioglitazone.
Estonian: On teada, et pioglitasooni samaaegne manustamine rifampitsiiniga (tsütokroom P4502C8 indutseerija) toob kaasa pioglitasooni kontsentratsioonikõvera aluse pindala vähenemise 54% võrra.
English: Glidipion 30 mg tablets
Estonian: Glidipion 30 mg tabletid
English: Co-administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) is reported to result in a 3-fold increase in AUC of pioglitazone.
Estonian: On teada, et pioglitasooni ja gemfibrosiili (tsütokroom P4502C8 inhibiitor) samaaegne manustamine toob kaasa pioglitasooni kontsentratsioonikõvera aluse pindala kolmekordse suurenemise.
English: Post-marketing reports of new-onset or worsening diabetic macular oedema with decreased visual acuity have been reported with thiazolidinediones, including pioglitazone.
Estonian: Turustusjärgselt on tiasolidiindioonide sh pioglitasooni kasutamisel teatatud diabeetilise makulaarse ödeemi esmakordsest tekkest või süvenemisest koos vähenenud nägemisteravusega.
English: Tel: +4021 230 65 24
Estonian: Teva Pharmaceuticals S.R.L Tel: +4021 230 65 24
English: Glidipion 45 mg tablets
Estonian: Glidipion 45 mg tabletid
English: Bladder cancer has been experienced uncommonly (up to 1 in 100 people) in patients taking pioglitazone.
Estonian: Aeg-ajalt (kuni 1-l kasutajal 100'st) on pioglitasooni võtvatel patsientidel täheldatud põievähki.
English: as dual oral therapy in combination with - metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin.
Estonian: kahe ravimi kombinatsioonis insuliiniga II tüüpi diabeediga täiskasvanud (eriti ülekaalulistele) patsientidele, kellele on metformiini maksimaalsetest talutavatest annustest sõltumata ebapiisav glükeemiline insuliini kontroll.
English: Glidipion 15 mg tablets
Estonian: Glidipion 15 mg tabletid
English: 1 Postmarketing reports of hypersensitivity reactions in patients treated with pioglitazone have been reported.
Estonian: Pioglitasooniga ravitud patsientidel on turuletulekujärgselt teatatud ülitundlikkusreaktsioonidest..
English: Glidipion 15 mg tablets are white, round, flat, bevelled, 5.5 mm in diameter and engraved with ‘TZ15' on one side.
Estonian: Glidipion 15 mg tabletid on valged, ümmargused, lamedad, tahutud, 5,5 mm läbimõõduga ja ühele küljele on sisse graveeritud „TZ15“.
English: Breastfeeding
Estonian: Pioglitazonum
English: Your doctor will ask you to have blood tests periodically during treatment with Glidipion.
Estonian: Võttes Glidipion'i tablette, palub teie arst teil regulaarsete intervallide järel anda vereanalüüsi.
English: Glidipion 45 mg tablets pioglitazone
Estonian: Glidipion 45 mg tabletid pioglitasoon
English: A cardiovascular outcome study of pioglitazone has been performed in patients under 75 years with type 2 diabetes mellitus and pre-existing major macrovascular disease.
Estonian: II tüüpi diabeediga ja eelneva makrovaskulaarse haigusega üle 75 aastaste patsientide seas viidi läbi kardiovaskulaarseid kaugtulemusi hindav pioglitasooni uuring.
English: The tablets are white, round, flat, bevelled, 5.5 mm in diameter and engraved with ‘TZ15' on one side.
Estonian: Tabletid on valged, ümmargused, lamedad, längus servadega, 5,5 mm läbimõõduga ja ühele küljele on sisse graveeritud „TZ15“.
English: If you experience this side effect, talk to your doctor as soon as possible.
Estonian: Kui Teil esineb sellist kõrvaltoimet, võtke võimalikult kiiresti oma arstiga ühendust.
English: Glidipion 45 mg tablets are white, round, flat, bevelled, 8 mm in diameter and engraved with ‘TZ45' on one side.
Estonian: Glidipion 45 mg tabletid on valged, ümmargused, lamedad, tahutud, 8 mm läbimõõduga ja ühele küljele on sisse graveeritud „TZ45“.
English: Fri.
Estonian: INN.
English: Glidipion 30 mg tablets are white, round, flat, bevelled, 7 mm in diameter and engraved with ‘TZ30' on one side.
Estonian: Glidipion 30 mg tabletid on valged, ümmargused, lamedad, tahutud, 7 mm läbimõõduga ja ühele küljele on sisse graveeritud „TZ30“.
English: There may be an increased possibility of becoming pregnant because you may ovulate again when you take Glidipion.
Estonian: Kui te võtate Glidipion'i, võib teil esineda ovulatsioon, mis suurendab rasestumise võimalust.
English: Each tablet contains 45 mg pioglitazone (as hydrochloride).
Estonian: Üks tablett sisaldab 45 mg pioglitasooni (vesinikkloriidina).
English: Pregnancy
Estonian: Luumurrud
English: The other side effects that have been experienced by some patients taking pioglitazone:
Estonian: Patsientidel, kes on kasutanud Glidipion'i, on esinenud järgmisi kõrvaltoimeid:
English: Each tablet contains 30 mg pioglitazone (as hydrochloride).
Estonian: Üks tablett sisaldab 30 mg pioglitasooni (vesinikkloriidina).
English: - The active substance is pioglitazone.
Estonian: Mida Glidipion sisaldab - Toimeaine on pioglitasoon.
English: If you experience any of these, talk to your doctor as soon as possible.
Estonian: Kui te märkate endal mõnda neist sümptomitest, pöörduge niipea kui võimalik oma arsti poole.
English: Contents of the pack and other information What Glidipion contains
Estonian: Võimalikud kõrvaltoimed Kuidas Glidipion'i säilitada Pakendi sisu ja muu teave
English: Heart failure has been experienced commonly (up to 1 in 10 people) in patients taking pioglitazone in combination with insulin.
Estonian: Pioglitasooni koos insuliiniga võtvatel patsientidel on sageli esinenud südamepuudulikkust (kuni 1-l kasutajal 10'st).
English: Each tablet contains 15 mg pioglitazone (as hydrochloride).
Estonian: Üks tablett sisaldab 15 mg pioglitasooni (vesinikkloriidina).
English: This leaflet was last revised in {MM/YYYY}.
Estonian: Infoleht viimati kooskõlastatud:
English: common common common common common blood creatine phospho-kinase increased common increased lactic dehydro-genase uncommon
Estonian: Uuringud kehakaalu suurenemine vere kreatiinfosfokinaasi taseme suurenemine
English: Hepatic impairment
Estonian: Südame häired Südamepuudulikkus
English: Rare cases of elevated liver enzymes and hepatocellular dysfunction have occurred in post-marketing experience.
Estonian: Müügijärgselt on harva teatatud maksaensüümide aktiivsuse tõusust ja hepatotsellulaarsest funktsioonihäirest.
English: Nervous system disorders hypo-aesthesia common common common common common headache common uncommon dizziness common insomnia uncommon uncommon uncommon uncommon uncommon
Estonian: Silma kahjustused nägemishäired aeg-ajalt makulaarne ödeem teadmata teadmata teadmata teadmata teadmata
English: Glidipion 30 mg tablets pioglitazone
Estonian: RAVIMPREPARAADI NIMETUS Glidipion 30 mg tabletid pioglitazonum
English: Glidipion 15 mg tablets pioglitazone
Estonian: RAVIMPREPARAADI NIMETUS Glidipion 15 mg tabletid pioglitazonum
English: Symptomatic treatment may be required.
Estonian: Vajalik võib olla sümptomaatiline ravi.
English: The relative reduction in mastitis incidence was 26%.
Estonian: Mastiidi esinemissageduse suhteline vähenemine oli 26%.
English: Imrestor pegbovigrastim
Estonian: Imrestor pegbovigrastiim
English: The intervals between the two injections should not be less than 3 days or more than 17 days.
Estonian: Kahe süsti vaheline intervall ei tohi olla lühem kui 3 päeva või pikem kui 17 päeva.
English: The full EPAR for Imrestor can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Imrestori kohta on ameti veebilehel: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: What is Imrestor and what is it used for?
Estonian: Mis on Imrestor ja milleks seda kasutatakse?
English: Headache and bone and muscle pain may occur.
Estonian: Võivad esineda peavalu ning luu- ja lihasvalu.
English: These clinical signs typically appear between 30 minutes and 2 hours after the first dose and resolve within 2 hours.
Estonian: Need kliinilised nähud tekivad tüüpiliselt 30 minutit kuni 2 tundi pärast esimest annust ja lahenevad 2 tunni jooksul.
English: In a field trial involving 2465 cows the incidence of clinical mastitis during days 3 to 30 of milk production was 9.1% (113/1235) in the Imrestor-treated group compared with 12.4% (152/1230) in the group given a dummy injection.
Estonian: 2465 lehma väliuuringus oli kliinilise mastiidi esinemissagedus piimaproduktsiooni 3. kuni 30. päeval 9,1% (113/1235) Imrestoriga ravitud rühmas võrreldes 12,4%-ga (152/1230) rühmas, kus lehmad said näiva süsti.
English: Neutrophils are part of the immune system (the body's natural defences) and help to fight infection.
Estonian: Neutrofiilid on osa immuunsüsteemist (organismi loomulikust kaitsemehhanismist) ja aitavad võidelda nakkustega.
English: Other information about Imrestor
Estonian: Muu teave Imrestori kohta
English: This summary was last updated in October 2015.
Estonian: Kokkuvõtte viimane uuendus: 10-2015.
English: Why is Imrestor approved?
Estonian: Miks Imrestor heaks kiideti?
English: A second injection is given within 24 hours after calving.
Estonian: Teine süst tehakse 24 tunni jooksul pärast poegimist.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Imrestor's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Veterinaarravimite komitee järeldas, et Imrestori kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Pegbovigrastim is a modified form of a natural protein, bovine granulocyte colony stimulating factor (bG-CSF), that stimulates the production and activity of a type of white blood cells called neutrophils.
Estonian: Pegbovigrastiim on loodusliku valgu - veiste granulotsüütide kolooniaid stimuleeriva faktori (bGCSF) modifitseeritud vorm, mis stimuleerib neutrofiilideks nimetatavate teatud tüüpi valgevererakkude tootmist ja aktiivsust.
English: There may also be other effects including nausea (feeling sick), and rashes or other hypersensitivity reactions (e.g. breathing difficulties and low blood pressure).
Estonian: Samuti võivad esineda muud toimed, sealhulgas iiveldus ja lööbed või muud ülitundlikkusreaktsioonid (nt hingamisraskused ja madal vererõhk).
English: The European Commission granted a marketing authorisation valid throughout the EU for Imrestor on
Estonian: Euroopa Komisjon andis Imrestori müügiloa, mis kehtib kogu Euroopa Liidu territooriumil,
English: Gloves should be removed and hands and exposed skin washed after use.
Estonian: Kindad tuleb pärast kasutamist eemaldada ning käed ja ravimiga kokkupuutunud nahk pesta.
English: The content of a single pre-filled syringe is given by injection under the skin (subcutaneously) to a dairy cow/heifer preferably 7 days before the anticipated date of calving.
Estonian: Ühe eeltäidetud süstla sisu süstitakse piimalehma/mullika naha alla (subkutaanselt) eelistatavalt 7 päeva enne eeldatavat poegimiskuupäeva.
English: It is not intended to provide practical advice on how to use Imrestor.
Estonian: Hindamisaruandes ei anta Imrestori kasutamise praktilisi nõuandeid.
English: The withdrawal period for meat and milk from cows treated with Imrestor is ‘zero' days, which means there is no mandatory waiting time.
Estonian: Imrestoriga ravitud veiste liha ja piima keeluaeg on 0 päeva, mis tähendab, et keeluaega ei ole.
English: By giving Imrestor, the number of neutrophils in the blood is increased, which is an aid to reduce the risk of infections of the udder that might lead to mastitis.
Estonian: Imrestori manustamisel suureneb neutrofiilide arv veres, mis aitab kaasa mastiidi tekkeni viivate udaranakkuste riski vähendamisele.
English: The most common side effects with Imrestor (which may affect up to 1 in 100 cows) are non-typical anaphylactoid (allergic) reactions seen as swelling of mucous membranes (notably vulva and eyelid), skin reactions, increased respiration rate and salivation.
Estonian: Imrestori kõige sagedamad kõrvalnähud (võivad esineda kuni 1 loomal 100st) on ebatüüpilised anafülaktoidsed (allergilised) reaktsioonid, mis väljenduvad limaskestade turse (eriti vulva ja silmalaugude turse), nahareaktsioonide, suurenenud hingamissageduse ja süljeeritusena.
English: This is a summary of the European public assessment report (EPAR) for Imrestor.
Estonian: See on ravimi Imrestor Euroopa avaliku hindamisaruande kokkuvõte.
English: Imrestor is a veterinary medicine used as an aid in a herd management programme, to reduce the risk of clinical mastitis (inflammation of the udder) in dairy cows and heifers (cows that have not produced a calf) during the 30 days following calving.
Estonian: Imrestor on veterinaarravim, mida kasutatakse karja raviprogrammis kliinilise mastiidi (udarapõletiku) tekkeriski vähendamiseks piimalehmadel ja mullikatel (lehmad, kes ei ole poeginud) 30 päeva jooksul pärast poegimist.
English: How does Imrestor work?
Estonian: Kuidas Imrestor toimib?
English: What are the risks associated with Imrestor?
Estonian: Mis riskid Imrestoriga kaasnevad?
English: It contains the active substance pegbovigrastim.
Estonian: Ravim sisaldab toimeainena pegbovigrastiimi.
English: For the full list of all side effects reported with Imrestor, see the package leaflet.
Estonian: Imrestori kohta teatatud kõrvaltoimete täielik loetelu on pakendi infolehel.
English: For practical information about using Imrestor, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Estonian: Kui loomaomanikud või -pidajad vajavad Imrestori kasutamise praktilisi nõuandeid, peavad nad lugema pakendi infolehte või pöörduma oma veterinaararsti või apteekri poole.
English: What benefits of Imrestor have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Imrestori kasulikkus?
English: People who are hypersensitive (allergic) to pegbovigrastim should avoid contact with Imrestor.
Estonian: Kokkupuudet Imrestoriga peavad vältima isikud, kes on pegbovigrastiimi suhtes ülitundlikud (allergilised).
English: How is Imrestor used?
Estonian: Kuidas Imrestorit kasutatakse?
English: Personal protective equipment consisting of gloves should be worn when handling broken or damaged syringes.
Estonian: Katkiste või kahjustatud süstalde käsitsemisel tuleb kasutada järgmisi isikukaitsevahendeid: kindad.
English: The medicine can only be obtained with a prescription and is available as a solution for injection in pre-filled syringes.
Estonian: Imrestorit turustatakse süstelahusena eeltäidetud süstaldes.
English: The European Commission granted a marketing authorisation valid throughout the EU for Sedadex on 12 August 2016.
Estonian: Euroopa Komisjon andis Sedadexi müügiloa, mis kehtib kogu Euroopa Liidus, 12. augustil 2016.
English: The company provided information on the quality and manufacture of Sedadex.
Estonian: Ettevõte esitas Sedadexi kvaliteedi ja tootmise andmed.
English: The full EPAR for Sedadex can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Sedadexi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: The Committee recommended that Sedadex be approved for use in the EU.
Estonian: Komitee soovitas Sedadexi kasutamise Euroopa Liidus heaks kiita.
English: Sedadex dexmedetomidine
Estonian: Sedadex deksmedetomidiin
English: What is Sedadex and what is it used for?
Estonian: Mis on Sedadex ja milleks seda kasutatakse?
English: Since noradrenaline is involved in maintaining alertness and arousal, reducing its release decreases the level of consciousness, including the sensation of pain.
Estonian: Et noradrenaliin on seotud erksuse ja erutuse säilitamisega, väheneb selle vabanemise vähendamisel teadvuse tase, sealhulgas valuaisting.
English: It is not intended to provide practical advice on how to use Sedadex.
Estonian: Hindamisaruandes ei anta Sedadexi kasutamise praktilisi nõuandeid.
English: The duration and depth of sedation and analgesia relate to the dose that is used.
Estonian: analgeesia kestus ning sügavus olenevad kasutatavast annusest.
English: • Sedadex can also be used in dogs to provide pain relief and deep sedation when carrying out medical procedures and minor surgery where it is used in combination with butorphanol (a sedative and analgesic).
Estonian: • Sedadexi tohib koertel kasutada ka valu leevendamiseks ja sügavaks sedatsiooniks meditsiiniliste protseduuride ja väiksemate operatsioonide korral koos butorfanooliga (sedatiivne aine ja analgeetikum).
English: Other information about Sedadex?
Estonian: Muu teave Sedadexi kohta
English: This is a summary of the European public assessment report (EPAR) for Sedadex.
Estonian: See on ravimi Sedadex Euroopa avaliku hindamisaruande kokkuvõte.
English: Because Sedadex is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Sedadex on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Dexmedetomidine is closely related to another substance used to sedate animals, medetomidine, that has been used in veterinary medicine for many years.
Estonian: Deksmedetomidiin sarnaneb väga teise loomade sedatsiooniks kasutatava aine medetomidiiniga, mida on veterinaarias kasutatud aastaid.
English: Why is Sedadex approved?
Estonian: Miks Sedadex heaks kiideti?
English: Sedadex is a medicine used to sedate (calm down) and relieve pain in dogs and cats:
Estonian: Sedadex on ravim, mida kasutatakse koerte ja kasside sedatsiooniks (rahustamiseks) ja valu leevendamiseks järgmistel näidustustel:
English: The dose in each species depends on the body surface area in dogs (calculated using bodyweight) and bodyweight in cats, and on the use, type of injection and any other medicines that are being used.
Estonian: Annus oleneb koertel kehapindalast (arvutatakse kehamassi järgi) ja kassidel kehamassist, samuti kasutusviisist, süstimisviisist ja muudest kasutatavatest ravimitest.
English: No additional studies were needed as Sedadex is a generic medicine that is given by injection, is similar in composition to, and contains the same active substance as, the reference medicine, Dexdomitor.
Estonian: Lisauuringuid ei olnud vaja, sest Sedadex on süstitav geneeriline ravim, mille koostis on sarnane võrdlusravimiga Dexdomitor ja mis sisaldab sama toimeainet.
English: This means that Sedadex is similar to a ‘reference medicine' already authorised in the EU called Dexdomitor.
Estonian: See tähendab, et Sedadex on sarnane võrdlusravimiga Dexdomitor, millel juba on Euroopa Liidus müügiluba.
English: A neurotransmitter is a substance that nerve cells use to communicate with neighbouring cells.
Estonian: Neurotransmitterid on keemilised ained, mis vahendavad närvirakkude vahelisi signaale.